Contact
searchSearch
HMP Global
Login

Psychedelics Topic Center

Cape Cod Symposium Speakers
Overcoming Perception Barriers and Promoting Safe Access to Psychedelics
09/05/2024
Cape Cod Symposium faculty members Raghu Appasani, MD, PC, Gaetano Vaccaro, PhD, CSAT, and Kaci Hohmann, JD, discuss the barriers and opportunities of psychedelic therapy in conventional psychiatric medicine and addiction recovery
Cape Cod Symposium faculty members Raghu Appasani, MD, PC, Gaetano Vaccaro, PhD, CSAT, and Kaci Hohmann, JD, discuss the barriers and opportunities of psychedelic therapy in conventional psychiatric medicine and addiction recovery
Cape Cod Symposium faculty...
09/05/2024
Psychiatry & Behavioral Health
From Psychiatry & Behavioral Health
Cape Cod Symposium Speakers
Q&As
Exploring the Therapeutic Potential of Psychedelic Treatments in Psychiatry
09/05/2024
Cape Cod Symposium faculty members Raghu Appasani, MD, PC, Gaetano Vaccaro, PhD, CSAT, and Kaci Hohmann, JD, explore the therapeutic benefits of psychedelics, how psychedelics function as adjunctive therapies, and key legal considerations.
Cape Cod Symposium faculty members Raghu Appasani, MD, PC, Gaetano Vaccaro, PhD, CSAT, and Kaci Hohmann, JD, explore the therapeutic benefits of psychedelics, how psychedelics function as adjunctive therapies, and key legal considerations.
Cape Cod Symposium faculty...
09/05/2024
Psychiatry & Behavioral Health
From Psychiatry & Behavioral Health
fda building sign
News
FDA Rejection of MDMA-Assisted Therapy for PTSD Divides Psychedelic Stakeholders
08/16/2024
Brionna Mendoza
The US Food and Drug Administration (FDA) last week rejected the new drug application (NDA) from Lykos Therapeutics for midomafetamine (MDMA) capsules for the treatment of post-traumatic stress disorder (PTSD) in conjunction with...
The US Food and Drug Administration (FDA) last week rejected the new drug application (NDA) from Lykos Therapeutics for midomafetamine (MDMA) capsules for the treatment of post-traumatic stress disorder (PTSD) in conjunction with...
The US Food and Drug...
08/16/2024
Psych Congress Network
Secondary Analysis Shows Which Patients With TRD Benefit Most From Ketamine
News
Secondary Analysis Shows Which Patients With TRD Benefit Most From Ketamine
07/24/2024
Jolynn Tumolo
Ketamine was associated with greater treatment response than electroconvulsive therapy in patients with nonpsychotic treatment-resistant depression who had moderately severe or severe pretreatment symptoms and who initiated treatment as...
Ketamine was associated with greater treatment response than electroconvulsive therapy in patients with nonpsychotic treatment-resistant depression who had moderately severe or severe pretreatment symptoms and who initiated treatment as...
Ketamine was associated with...
07/24/2024
Psych Congress Network
andrew penn
Videos
Decoding the FDA Committee's Decision to Reject MDMA-Assisted Therapy: Part 2
07/01/2024
Andrew Penn, RN, MS, NP, CNS, APRN-BC
Andrew Penn, MS, PMHNP, discusses the recent vote by the FDA's advisory committee (PDAC) against an MDMA-based therapy for the treatment of PTSD in adults and sheds light on what this means for the future of PTSD treatment.
Andrew Penn, MS, PMHNP, discusses the recent vote by the FDA's advisory committee (PDAC) against an MDMA-based therapy for the treatment of PTSD in adults and sheds light on what this means for the future of PTSD treatment.
Andrew Penn, MS, PMHNP,...
07/01/2024
Psych Congress Network
andrew penn
Videos
Decoding the FDA Committee's Decision to Reject MDMA-Assisted Therapy With Andrew Penn, MS, PMHNP
06/21/2024
Andrew Penn, MS, PMHNP, discusses the recent vote by the FDA's advisory committee (PDAC) against an MDMA-based therapy for the treatment of PTSD in adults and sheds light on what this means for the future of PTSD treatment.
Andrew Penn, MS, PMHNP, discusses the recent vote by the FDA's advisory committee (PDAC) against an MDMA-based therapy for the treatment of PTSD in adults and sheds light on what this means for the future of PTSD treatment.
Andrew Penn, MS, PMHNP,...
06/21/2024
Psych Congress Network
FDA
News
FDA Advisory Committee Rejects First MDMA Treatment for PTSD
06/06/2024
Meagan Thistle
FDA committee rejected an MDMA-based therapy for adult PTSD treatment due to concerns about its effectiveness and the reliability of the data, despite positive study results.
FDA committee rejected an MDMA-based therapy for adult PTSD treatment due to concerns about its effectiveness and the reliability of the data, despite positive study results.
FDA committee rejected an...
06/06/2024
Psych Congress Network
ketamine brain image
News
Study Findings Support Esketamine and Psilocybin as Effective TRD Treatments
05/14/2024
Meagan Thistle
To address the challenges and “inadequate outcomes” with monoamine-based therapies, a Toronto-based research team investigated novel alternatives for TRD.
To address the challenges and “inadequate outcomes” with monoamine-based therapies, a Toronto-based research team investigated novel alternatives for TRD.
To address the challenges and...
05/14/2024
Psych Congress Network
News
CPT III Codes for Psychedelic-Assisted Therapies Take Effect
01/05/2024
Tom Valentino
The temporary codes, which went into effect this week, allow providers to seek coverage and reimbursement for delivery of psychedelic-assisted therapies, pending their approval by the FDA.
The temporary codes, which went into effect this week, allow providers to seek coverage and reimbursement for delivery of psychedelic-assisted therapies, pending their approval by the FDA.
The temporary codes, which went...
01/05/2024
Psych Congress Network
News
MAPS PBC Submits New Drug Application for MDMA-Assisted Therapy for PTSD
12/12/2023
MAPS Public Benefit Corporation’s new drug application to the US Food and Drug Administration for the use of MDMA in combination with psychotherapy to treat post-traumatic stress disorder is the first filing to the FDA for any...
MAPS Public Benefit Corporation’s new drug application to the US Food and Drug Administration for the use of MDMA in combination with psychotherapy to treat post-traumatic stress disorder is the first filing to the FDA for any...
MAPS Public Benefit...
12/12/2023
Psych Congress Network
News
Use of Psilocbyin in Bipolar II Treatment Clinical Trial Produces Strong Results
12/12/2023
Tom Valentino
In a recent trial conducted by Sheppard Pratt researchers, 80% of participants with treatment-resistant bipolar II met the criteria for remission 12 weeks after treatment that included psilocybin and therapy.
In a recent trial conducted by Sheppard Pratt researchers, 80% of participants with treatment-resistant bipolar II met the criteria for remission 12 weeks after treatment that included psilocybin and therapy.
In a recent trial conducted by...
12/12/2023
Psych Congress Network

News Articles

fda building sign
News
FDA Rejection of MDMA-Assisted Therapy for PTSD Divides Psychedelic Stakeholders
08/16/2024
Brionna Mendoza
The US Food and Drug Administration (FDA) last week rejected the new drug application (NDA) from Lykos Therapeutics for midomafetamine (MDMA) capsules for the treatment of post-traumatic stress disorder (PTSD) in conjunction with...
The US Food and Drug Administration (FDA) last week rejected the new drug application (NDA) from Lykos Therapeutics for midomafetamine (MDMA) capsules for the treatment of post-traumatic stress disorder (PTSD) in conjunction with...
The US Food and Drug...
08/16/2024
Psych Congress Network
Secondary Analysis Shows Which Patients With TRD Benefit Most From Ketamine
News
Secondary Analysis Shows Which Patients With TRD Benefit Most From Ketamine
07/24/2024
Jolynn Tumolo
Ketamine was associated with greater treatment response than electroconvulsive therapy in patients with nonpsychotic treatment-resistant depression who had moderately severe or severe pretreatment symptoms and who initiated treatment as...
Ketamine was associated with greater treatment response than electroconvulsive therapy in patients with nonpsychotic treatment-resistant depression who had moderately severe or severe pretreatment symptoms and who initiated treatment as...
Ketamine was associated with...
07/24/2024
Psych Congress Network
FDA
News
FDA Advisory Committee Rejects First MDMA Treatment for PTSD
06/06/2024
Meagan Thistle
FDA committee rejected an MDMA-based therapy for adult PTSD treatment due to concerns about its effectiveness and the reliability of the data, despite positive study results.
FDA committee rejected an MDMA-based therapy for adult PTSD treatment due to concerns about its effectiveness and the reliability of the data, despite positive study results.
FDA committee rejected an...
06/06/2024
Psych Congress Network
ketamine brain image
News
Study Findings Support Esketamine and Psilocybin as Effective TRD Treatments
05/14/2024
Meagan Thistle
To address the challenges and “inadequate outcomes” with monoamine-based therapies, a Toronto-based research team investigated novel alternatives for TRD.
To address the challenges and “inadequate outcomes” with monoamine-based therapies, a Toronto-based research team investigated novel alternatives for TRD.
To address the challenges and...
05/14/2024
Psych Congress Network
News
CPT III Codes for Psychedelic-Assisted Therapies Take Effect
01/05/2024
Tom Valentino
The temporary codes, which went into effect this week, allow providers to seek coverage and reimbursement for delivery of psychedelic-assisted therapies, pending their approval by the FDA.
The temporary codes, which went into effect this week, allow providers to seek coverage and reimbursement for delivery of psychedelic-assisted therapies, pending their approval by the FDA.
The temporary codes, which went...
01/05/2024
Psych Congress Network
News
MAPS PBC Submits New Drug Application for MDMA-Assisted Therapy for PTSD
12/12/2023
MAPS Public Benefit Corporation’s new drug application to the US Food and Drug Administration for the use of MDMA in combination with psychotherapy to treat post-traumatic stress disorder is the first filing to the FDA for any...
MAPS Public Benefit Corporation’s new drug application to the US Food and Drug Administration for the use of MDMA in combination with psychotherapy to treat post-traumatic stress disorder is the first filing to the FDA for any...
MAPS Public Benefit...
12/12/2023
Psych Congress Network
News
Use of Psilocbyin in Bipolar II Treatment Clinical Trial Produces Strong Results
12/12/2023
Tom Valentino
In a recent trial conducted by Sheppard Pratt researchers, 80% of participants with treatment-resistant bipolar II met the criteria for remission 12 weeks after treatment that included psilocybin and therapy.
In a recent trial conducted by Sheppard Pratt researchers, 80% of participants with treatment-resistant bipolar II met the criteria for remission 12 weeks after treatment that included psilocybin and therapy.
In a recent trial conducted by...
12/12/2023
Psych Congress Network
News
Microdosing Associated With Increased Mindfulness, Lower Neuroticism in ADHD Patients
11/28/2023
Tom Valentino
A study conducted by researchers in the Netherlands has found that microdosing psychedelics for 4 weeks induced an increase in mindfulness and a decrease in neuroticism among adults diagnosed with attention-deficit/hyperactivity disorder...
A study conducted by researchers in the Netherlands has found that microdosing psychedelics for 4 weeks induced an increase in mindfulness and a decrease in neuroticism among adults diagnosed with attention-deficit/hyperactivity disorder...
A study conducted by researchers...
11/28/2023
Psych Congress Network
News
Compass Pathways Initiates Phase 3 Study of Psilocybin for Treatment-Resistant Depression
11/27/2023
Tom Valentino
Compass Pathways, which recently opened a new research center in London, has begun a multi-site study of investigational psilocybin treatment of treatment-resistant depression.
Compass Pathways, which recently opened a new research center in London, has begun a multi-site study of investigational psilocybin treatment of treatment-resistant depression.
Compass Pathways, which recently...
11/27/2023
Psych Congress Network
Christopher Nicholas, PhD
News
Psychedelics Show Potential to Improve SUD Treatment Outcomes
10/31/2023
Tom Valentino
With drug overdose deaths continuing to climb, Sana Symposium presenter Christopher Nicholas, PhD, said studies suggest that incorporating the use of psychedelics into treatment modalities could improve outcomes.
With drug overdose deaths continuing to climb, Sana Symposium presenter Christopher Nicholas, PhD, said studies suggest that incorporating the use of psychedelics into treatment modalities could improve outcomes.
With drug overdose deaths...
10/31/2023
Psych Congress Network
stethoscope, pills, and a brain
News
Stimulant Treatment for ADHD Associated With Psychosis and BD
09/25/2025
Maria Mantas
Stimulant use for the treatment of attention-deficit/hyperactivity disorder (ADHD) was associated with higher occurrence of psychotic symptoms, psychotic disorders, and bipolar disorder (BD), according to a systematic review.
Stimulant use for the treatment of attention-deficit/hyperactivity disorder (ADHD) was associated with higher occurrence of psychotic symptoms, psychotic disorders, and bipolar disorder (BD), according to a systematic review.
Stimulant use for the treatment...
09/25/2025
Psych Congress Network
Katherine Warburton, Stephen Stahl, and Roberto Carrara
News
Breaking the Cycle of Criminalization: Keynote Address Tackles Neuroethics, Justice Reform, and Patient Autonomy at Psych Congress 2025
09/19/2025
Maria Mantas
Discussions of ethical intervention, patient autonomy, and justice reform took center stage during the keynote address at the 2025 Psych Congress on Wednesday evening.
Discussions of ethical intervention, patient autonomy, and justice reform took center stage during the keynote address at the 2025 Psych Congress on Wednesday evening.
Discussions of ethical...
09/19/2025
Psych Congress Network
DNA strand
News
Pharmacogenomic Test Improves MDD Response and Remission Outcomes
09/15/2025
Jolynn Tumolo
Clinician use of a specific weighted multigene pharmacogenomic (PGx) test significantly improved outcomes in adult patients with major depressive disorder (MDD) with at least 1 treatment failure, according to meta-analysis results.
Clinician use of a specific weighted multigene pharmacogenomic (PGx) test significantly improved outcomes in adult patients with major depressive disorder (MDD) with at least 1 treatment failure, according to meta-analysis results.
Clinician use of a specific...
09/15/2025
Psych Congress Network
fda building sign
News
FDA Approves TMS Device for Major Depressive Disorder in Adolescents
09/11/2025
Brionna Mendoza
The US Food and Drug Administration (FDA) approved on Wednesday the Apollo Transcranial Magnetic Stimulation (TMS) Therapy devices for the adjunctive treatment of major depressive disorder (MDD) in adolescents.
The US Food and Drug Administration (FDA) approved on Wednesday the Apollo Transcranial Magnetic Stimulation (TMS) Therapy devices for the adjunctive treatment of major depressive disorder (MDD) in adolescents.
The US Food and Drug...
09/11/2025
Psych Congress Network
cannabis plant and CBD oil
News
High Levels of THC in Cannabis Products Associated With Mental Health Risks
09/11/2025
Maria Mantas
Cannabis products that contained high concentrations of delta-9-tetrahydrocannabinol (THC) were associated with psychosis, schizophrenia, and cannabis use disorder (CUD), according to a systematic review.
Cannabis products that contained high concentrations of delta-9-tetrahydrocannabinol (THC) were associated with psychosis, schizophrenia, and cannabis use disorder (CUD), according to a systematic review.
Cannabis products that contained...
09/11/2025
Psych Congress Network
child embraces mother
News
Child Depression During COVID-19 Pandemic Associated With Subsequent Maternal Depression
09/02/2025
Maria Mantas
Child depression at ages 10 and 11 years during the COVID-19 pandemic was significantly associated with later maternal depression, according to longitudinal study results.
Child depression at ages 10 and 11 years during the COVID-19 pandemic was significantly associated with later maternal depression, according to longitudinal study results.
Child depression at ages 10 and...
09/02/2025
Psych Congress Network
An orange prescription container with generic pills spilling out in front of it
News
Early ADHD Drug Treatment Linked With Reduced Risk of Suicide, Substance Misuse, and Other Adverse Outcomes
08/27/2025
Jolynn Tumolo
Patients with attention-deficit/hyperactivity disorder (ADHD) who began drug treatment within 3 months of diagnosis had significantly reduced rates of suicidal behaviors, substance misuse, traffic accidents, and criminality.
Patients with attention-deficit/hyperactivity disorder (ADHD) who began drug treatment within 3 months of diagnosis had significantly reduced rates of suicidal behaviors, substance misuse, traffic accidents, and criminality.
Patients with...
08/27/2025
Psych Congress Network
An illustrated picture shows two cartoon doctors, one holding up a magnifying glass to a cartoon brain.
News
Investigational App for Negative Schizophrenia Symptoms Meets Primary Trial Endpoint
08/25/2025
Jolynn Tumolo
An investigational prescription digital therapeutic targeting negative symptoms in patients with schizophrenia met its primary endpoint in a pivotal phase 3 randomized controlled study.
An investigational prescription digital therapeutic targeting negative symptoms in patients with schizophrenia met its primary endpoint in a pivotal phase 3 randomized controlled study.
An investigational prescription...
08/25/2025
Psych Congress Network
tired man rubs eyes
News
Vulnerability to Inflammation-Related Depression Exaggerated in Older Adults With Insomnia
08/18/2025
Jolynn Tumolo
Compared with older adults without insomnia, older adults with the sleep disorder experienced a 3-fold greater increase in depressed mood and depressive symptoms after exposure to an inflammatory challenge, according to study findings.
Compared with older adults without insomnia, older adults with the sleep disorder experienced a 3-fold greater increase in depressed mood and depressive symptoms after exposure to an inflammatory challenge, according to study findings.
Compared with older adults...
08/18/2025
Psych Congress Network
A woman lies in bed awake due to insomnia
News
Cannabinoids Produce Worse Sleep Outcomes in Small Pilot Study
08/15/2025
Brionna Mendoza
A single dose of tetrahydrocannabinol/cannabidiol (THC/CBD) resulted in worse sleep for study participants with insomnia.
A single dose of tetrahydrocannabinol/cannabidiol (THC/CBD) resulted in worse sleep for study participants with insomnia.
A single dose of...
08/15/2025
Neurology

Blogs

Ketamine Shows Promise in Treatment of Mental Health, Chronic Pain, Addiction
Perspectives
Ketamine Shows Promise in Treatment of Mental Health, Chronic Pain, Addiction
04/12/2021
Steven L. Mandel, MD
A report published by CDC in August 2020 showed huge increases in mental health issues during the time period April-June 2020 compared with the same time period the previous year. Instances of suicidal conditions increased 200%, anxiety...
A report published by CDC in August 2020 showed huge increases in mental health issues during the time period April-June 2020 compared with the same time period the previous year. Instances of suicidal conditions increased 200%, anxiety...
A report published by CDC in...
04/12/2021
Addiction Professional
Blog
Psychedelics in Group Therapy for HIV Survivors Shows Promising Results
10/02/2020
Andrew Penn, RN, MS, NP, CNS, APRN-BC
BLOG: In a recent study, the utilization of psychedelic medicine in group therapy was linked with reduced demoralization among long-term, gay-identified, male HIV survivors—an outcome with larger implications for overall healthcare.
BLOG: In a recent study, the utilization of psychedelic medicine in group therapy was linked with reduced demoralization among long-term, gay-identified, male HIV survivors—an outcome with larger implications for overall healthcare.
BLOG: In a recent study, the...
10/02/2020
Psych Congress Network
Blog
Psych Congress to Bring Psychedelic-Assisted Therapies Into Focus
09/03/2020
Andrew Penn, RN, MS, NP, CNS, APRN-BC
BLOG: Psychedelic-assisted therapies, once consigned to the fringes of psychiatric practice, are exploding into the mainstream of psychiatry and will take center stage at a Psych Congress preconference.
BLOG: Psychedelic-assisted therapies, once consigned to the fringes of psychiatric practice, are exploding into the mainstream of psychiatry and will take center stage at a Psych Congress preconference.
BLOG: Psychedelic-assisted...
09/03/2020
Psych Congress Network
Blog
Psychedelics and Wellness: What’s the Connection?
12/17/2019
Andrew Penn, RN, MS, NP, CNS, APRN-BC
BLOG: I sat down with Saundra Jain, MA, PsyD, LPC to better understand the connection between wellness and psychedelics.
BLOG: I sat down with Saundra Jain, MA, PsyD, LPC to better understand the connection between wellness and psychedelics.
BLOG: I sat down with Saundra...
12/17/2019
Psych Congress Network
Blog
The Psychedelic Aspect of Esketamine is an Opportunity, Not a Side Effect
05/23/2019
Andrew Penn, RN, MS, NP, CNS, APRN-BC
BLOG: Esketamine represents the first psychedelic treatment approved by the FDA for a psychiatric condition.
BLOG: Esketamine represents the first psychedelic treatment approved by the FDA for a psychiatric condition.
BLOG: Esketamine represents the...
05/23/2019
Psych Congress Network
Blog
A Turning Point for Psychedelics?
06/06/2018
Andrew Penn, RN, MS, NP, CNS, APRN-BC
BLOG: Michael Pollan, author of The Omnivore’s Dilemma and The Botany of Desire, has turned his spotlight of curiosity onto the subject of psychedelics with his new book How to Change Your Mind.
BLOG: Michael Pollan, author of The Omnivore’s Dilemma and The Botany of Desire, has turned his spotlight of curiosity onto the subject of psychedelics with his new book How to Change Your Mind.
BLOG: Michael Pollan, author of...
06/06/2018
Psych Congress Network
Blog
Depression as Disconnection: New Lessons From Psychedelic Psychotherapy Studies
11/02/2017
Andrew Penn, RN, MS, NP, CNS, APRN-BC
BLOG: Recent qualitative studies on subjects treated with psilocybin may begin to help us understand the subjective experience caused by the drug that may lead to its antidepressant effects.
BLOG: Recent qualitative studies on subjects treated with psilocybin may begin to help us understand the subjective experience caused by the drug that may lead to its antidepressant effects.
BLOG: Recent qualitative studies...
11/02/2017
Psych Congress Network
Blog
Psilocybin Studies: A New Ray of Hope for Psychiatry?
12/01/2016
Andrew Penn, RN, MS, NP, CNS, APRN-BC
BLOG: These studies were the latest findings showing that psychedelics, erroneously dismissed as mere intoxicants and swept up in the hysteria of the Nixon-era drug wars, could prove to be as important to psychiatry as penicillin was to...
BLOG: These studies were the latest findings showing that psychedelics, erroneously dismissed as mere intoxicants and swept up in the hysteria of the Nixon-era drug wars, could prove to be as important to psychiatry as penicillin was to...
BLOG: These studies were the...
12/01/2016
Psych Congress Network
Blog
Psychedelics: What to Tell Patients Today
08/25/2015
Andrew Penn, RN, MS, NP, CNS, APRN-BC
Psychedelic compounds are powerful, and they have great potential to help patients with intractable conditions. Yet any compound with that kind of power also has the potential to harm, and that harm should not be trivialized.
Psychedelic compounds are powerful, and they have great potential to help patients with intractable conditions. Yet any compound with that kind of power also has the potential to harm, and that harm should not be trivialized.
Psychedelic compounds are...
08/25/2015
Psych Congress Network
Blog
How Psychedelics May Be Used to Accelerate Psychotherapy
08/19/2015
Andrew Penn, RN, MS, NP, CNS, APRN-BC
Personal reports from treatment subjects are as compelling as the quantitative data.
Personal reports from treatment subjects are as compelling as the quantitative data.
Personal reports from treatment...
08/19/2015
Psych Congress Network
marc agronin md
Faculty Insights
Alzheimer Disease Prevention: Part 2
07/29/2024
Marc E. Agronin, MD
In this highly anticipated sequel to his 2022 blog, Marc Agronin, MD, geriatric psychiatry section editor at Psych Congress Network, offers deeper expert clinical insights on Alzheimer disease prevention.
In this highly anticipated sequel to his 2022 blog, Marc Agronin, MD, geriatric psychiatry section editor at Psych Congress Network, offers deeper expert clinical insights on Alzheimer disease prevention.
In this highly anticipated...
07/29/2024
Psych Congress Network
Rakesh Amin, MD.
Blog
Treating Schizophrenia: The Importance of Early Identification and Intervention
06/13/2023
Rakesh Amin, MD
Rakesh Amin, MD, discusses the importance of partnering with patients and caregivers to set treatment goals and the importance of introducing long-acting injectables earlier in the treatment of schizophrenia.
Rakesh Amin, MD, discusses the importance of partnering with patients and caregivers to set treatment goals and the importance of introducing long-acting injectables earlier in the treatment of schizophrenia.
Rakesh Amin, MD, discusses the...
06/13/2023
Psych Congress Network
Marc Agronin, MD.
Blog
Alzheimer Disease Prevention
08/30/2022
Marc E. Agronin, MD
Psych Congress Network Section Editor Mark Agronin, MD, provides expert clinical insights on reducing the risk for Alzheimer disease and delaying its onset and progression.
Psych Congress Network Section Editor Mark Agronin, MD, provides expert clinical insights on reducing the risk for Alzheimer disease and delaying its onset and progression.
Psych Congress Network Section...
08/30/2022
Psych Congress Network
Ed Jones, PhD
Blog
How Our Clinicians Can Help Fix the US Health Care System
07/28/2022
Ed Jones, PhD
Ed Jones, PhD, discusses the need for a clinical refocusing that includes broad access to psychosocial solutions and ensuring socially informed clinicians can help underserved communities.
Ed Jones, PhD, discusses the need for a clinical refocusing that includes broad access to psychosocial solutions and ensuring socially informed clinicians can help underserved communities.
Ed Jones, PhD, discusses the...
07/28/2022
Psych Congress Network
Ed Jones, PhD
Perspective
The Universal Behavior Model: A Comprehensive Approach to Integrated Care
07/21/2022
Ed Jones, PhD
Ed Jones, PhD: "We miss this psychosocial aspect of care today...What is missing?  We need psychotherapists based in primary care, often focused on mundane issues rather than the complexities of diagnosis or treatment."
Ed Jones, PhD: "We miss this psychosocial aspect of care today...What is missing?  We need psychotherapists based in primary care, often focused on mundane issues rather than the complexities of diagnosis or treatment."
Ed Jones, PhD: "We miss this...
07/21/2022
Psych Congress Network
Chan_Khan_Digital Mental Health
Blog
Who will use it? How to Get Digital Mental Health Apps Into the Hands of Patients
04/27/2022
Steven Chan, MD, MBA, and Burhan Ahmed Khan, MD, discuss how to encourage patients to use digital mental health apps.
Steven Chan, MD, MBA, and Burhan Ahmed Khan, MD, discuss how to encourage patients to use digital mental health apps.
Steven Chan, MD, MBA, and Burhan...
04/27/2022
Psychiatry & Behavioral Health
Chan_Khan_Digital Mental Health
Blog
How to Navigate Quality Issues With Mental Health Apps
04/21/2022
Steven Chan, MD, MBA, and Burhan Ahmed Khan, MD, navigating quality issues with digital mental health applications.
Steven Chan, MD, MBA, and Burhan Ahmed Khan, MD, navigating quality issues with digital mental health applications.
Steven Chan, MD, MBA, and Burhan...
04/21/2022
Psychiatry & Behavioral Health
Andrew Penn, RN, MS, NP, CNS, APRN-BC
Blog
How New NPs Can Find Mentors
03/04/2022
Andrew Penn, RN, MS, NP, CNS, APRN-BC
Andrew Penn, NP, explains mentoring, how to find one as an NP, and what to do when you have found a possible mentor. He gives practical advice, questions to ask, and avenues to find the right fit.
Andrew Penn, NP, explains mentoring, how to find one as an NP, and what to do when you have found a possible mentor. He gives practical advice, questions to ask, and avenues to find the right fit.
Andrew Penn, NP, explains...
03/04/2022
Psych Congress Network
Julie Bailey
Blog
How to Be a Safe Space for Someone
02/08/2022
In this blog, Julie Bailey, LCPC, shares her insights on providing a safe space for patients to discuss these social anxieties, as well as tips to share with patients about slowly reintegrating into life after COVID-19.
In this blog, Julie Bailey, LCPC, shares her insights on providing a safe space for patients to discuss these social anxieties, as well as tips to share with patients about slowly reintegrating into life after COVID-19.
In this blog, Julie Bailey,...
02/08/2022
Psych Congress Network
major depressive disorder
Blog
The Best and Worst Changes Brought On By the Pandemic
01/31/2022
Mental health advocate, Dorothy Watson shares her insights about the impact the pandemic has had on mental health and where we go from here.
Mental health advocate, Dorothy Watson shares her insights about the impact the pandemic has had on mental health and where we go from here.
Mental health advocate, Dorothy...
01/31/2022
Psych Congress Network

Interactive Features

Quiz
Quiz: Psilocybin Named Breakthrough Therapy for Which Condition?
12/10/2019
The US Food and Drug Administration (FDA) recently gave the Breakthrough Therapy designation to psilocybin for the treatment of which mental health condition?
The US Food and Drug Administration (FDA) recently gave the Breakthrough Therapy designation to psilocybin for the treatment of which mental health condition?
The US Food and Drug...
12/10/2019
Psych Congress Network
a cloud with three z's
Quiz
Test Your Knowledge – ADHD and Sleep: Why Non-Stimulants Might Be the Right Choice (Part 1)
09/19/2025
Can you optimize ADHD control and protect sleep? Take this quick quiz on viloxazine ER’s role in patients with nighttime challenges.
Can you optimize ADHD control and protect sleep? Take this quick quiz on viloxazine ER’s role in patients with nighttime challenges.
Can you optimize ADHD control...
09/19/2025
Psych Congress Network
Dr Greg Mattingly
Quiz
Test Your Knowledge – Viloxazine ER: A New Era in ADHD Treatment?
09/17/2025
How well do you know the clinical impact and unique mechanism of viloxazine ER? Take this short quiz to find out.
How well do you know the clinical impact and unique mechanism of viloxazine ER? Take this short quiz to find out.
How well do you know the...
09/17/2025
Psych Congress Network
Craig Chepke, MD, DFAPA
Quiz
Muscarinic Receptor-Based Options for Treatment-Resistant Schizophrenia
09/12/2025
Craig Chepke, MD, DFAPA
Do you remember the details of this interview with Dr Chepke?
Do you remember the details of this interview with Dr Chepke?
Do you remember the details of...
09/12/2025
Psych Congress Network
medication
Quiz
Test Your Knowledge: Study Results Link Non-Stimulant ADHD Therapy and Prescription Stimulant Misuse in Adolescents
09/09/2025
What does research reveal about the risk of non-stimulants? Test your understanding of ADHD treatment and stimulant misuse.
What does research reveal about the risk of non-stimulants? Test your understanding of ADHD treatment and stimulant misuse.
What does research reveal about...
09/09/2025
Psych Congress Network
Dr Rakesh Jain
Quiz
Test Your Knowledge – Targeting Hyperactivity and Impulsivity in Adolescents: A Look at Viloxazine ER
09/04/2025
Think you understand the role of non-stimulants in ADHD treatment? Take this quick quiz to test your knowledge of viloxazine ER.
Think you understand the role of non-stimulants in ADHD treatment? Take this quick quiz to test your knowledge of viloxazine ER.
Think you understand the role of...
09/04/2025
Psych Congress Network
Dr Rakesh Jain
Quiz
Test Your Knowledge: Dr Rakesh Jain on Nonstimulant Treatment Options for Pediatric ADHD
09/03/2025
How well do you know the evolving landscape of non-stimulant ADHD treatments? Take this quick quiz to find out.
How well do you know the evolving landscape of non-stimulant ADHD treatments? Take this quick quiz to find out.
How well do you know the...
09/03/2025
Psych Congress Network
Wooden blocks spelling QUIZ
Quiz
Test Your Knowledge: Viloxazine ER Added to Stimulant Treatment for Pediatric ADHD Appears Safe, Effective
09/02/2025
Can viloxazine ER enhance stimulant therapy in pediatric ADHD? Take this quick quiz to test your knowledge.
Can viloxazine ER enhance stimulant therapy in pediatric ADHD? Take this quick quiz to test your knowledge.
Can viloxazine ER enhance...
09/02/2025
Psych Congress Network
Drs Mattingly, Price, Amann Part 3
Quiz
Test Your Knowledge – Navigating ADHD Care Forward: The Future of ADHD
08/27/2025
Take this quick quiz to test your knowledge on combination treatment strategies, novel mechanisms, and how emerging data is reshaping care for complex patients of all ages.
Take this quick quiz to test your knowledge on combination treatment strategies, novel mechanisms, and how emerging data is reshaping care for complex patients of all ages.
Take this quick quiz to test...
08/27/2025
Psych Congress Network
Drs Mattingly, Price, Amann Part 2
Quiz
Test Your Knowledge – Real-World Data Deep Dive: Viloxazine ER Compared With Atomoxetine for ADHD Study
08/25/2025
Discover how viloxazine ER compares to atomoxetine in real-world ADHD treatment—test your knowledge with this short, expert-driven quiz.
Discover how viloxazine ER compares to atomoxetine in real-world ADHD treatment—test your knowledge with this short, expert-driven quiz.
Discover how viloxazine ER...
08/25/2025
Psych Congress Network
blocks spelling out the word "quiz"
Quiz
Initiating Clozapine in Patients With Schizophrenia
08/15/2025
In which of the following scenarios does the American Psychiatric Association (APA) recommend initiating clozapine in patients with schizophrenia?
In which of the following scenarios does the American Psychiatric Association (APA) recommend initiating clozapine in patients with schizophrenia?
In which of the following...
08/15/2025
Psych Congress Network

Posters

Adjunctive Treatment With Seltorexant Improved Patient-Reported Depressive Symptoms, Insomnia Symptoms, and Overall Health in Major Depressive Disorder With Insomnia
Background: We report secondary/exploratory endpoints assessing patient-reported depressive symptoms, insomnia symptoms, and health-related quality of life (HRQoL) from a phase 3, double-...
11/26/2024
Guiding antidepressant choice by applying deep learning approaches on individual patient-derived neurons: a window to drug efficacy in each patient
Depression treatment remains a significant clinical challenge due to the variability in patient responses to antidepressant medications. Outside of pharmacogenetic testing, established mo...
11/26/2024
Clinical effectiveness and persistence on esketamine nasal spray in patients with treatment-resistant depression overall and among transcranial magnetic stimulation-naïve subgroup
BACKGROUND: Esketamine nasal spray and transcranial magnetic stimulation (TMS) are used for treatment-resistant depression (TRD), but little is known about the sequence in which these the...
11/26/2024
Real-world clinical effectiveness of esketamine nasal spray based on the Montgomery-Asberg Depression Rating Scale (MADRS) among patients with treatment-resistant depression in the United States
BACKGROUND: Clinical trials for esketamine nasal spray in treatment resistant depression (TRD) often assess efficacy using Montgomery-Asberg Depression Rating Scale (MADRS)-based primary ...
11/26/2024
Response and remission on esketamine nasal spray in patients with treatment-resistant depression overall and among transcranial magnetic stimulation-naïve subgroup
BACKGROUND: Both esketamine nasal spray and transcranial magnetic stimulation (TMS) are indicated for treatment-resistant depression (TRD), but there are no guidelines on the sequence of...
11/26/2024
Comparison of Real-world Response and Remission among Patients with Treatment-Resistant Depression Treated with Esketamine Nasal Spray or Antipsychotic Augmentation
BACKGROUND: Esketamine nasal spray and second-generation antipsychotic augmentation (SGA) are approved therapies for treatment-resistant depression (TRD). Prospective randomized ESCAPE-TR...
11/26/2024
Effect of Centanafadine on AISRS Over 6 Weeks of Treatment in Adults with ADHD: A Pooled Analysis of Two Phase 3 Trials
TBD
11/26/2024
Impact of Centanafadine on the ASRS After 6 Weeks of Treatment of ADHD in Adults: A Pooled Analysis of Two Phase 3 Trials
Hypothesis/Objective: To evaluate the impact of centanafadine (CTN)—a norepinephrine, dopamine, serotonin reuptake inhibitor—on patient-reported assessment of the frequency of core sympto...
11/26/2024
Prescription Digital Therapeutics in Psychiatry: Virtual CME Advances Physician Knowledge and Confidence
Background: Digital therapeutic technologies (DTx) are emerging rapidly, and clinicians are challenged to understand their benefits and how they fit into practice. Physicians require educ...
11/26/2024
Assessing Participant Experience with KarXT Treatment Using In-Trial Qualitative Interviews: Perceived Effect on Symptoms During a Long-Term Phase 3 Trial in Schizophrenia
KarXT is a novel investigational muscarinic M1/M4 receptor agonist that, unlike currently available antipsychotics, does not directly block dopamine D2 receptors. A new drug application f...
11/26/2024

E-Learning

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

andrew and julie
Rapid Refresh
Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics
04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP, and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and...
04/11/2024
Psych Congress NP Institute
Amber Hoberg
Rapid Refresh
Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder
04/10/2024
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC,...
04/10/2024
Psych Congress NP Institute
Hoberg and Matthews
Clinical Pearls
Tolerability Testing in Long-Acting Injectable Prescriptions
04/03/2024
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for...
04/03/2024
Psych Congress NP Institute

Sign Up

Psych Congress Network Newsletter

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use